These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30552464)

  • 1. In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds.
    Fabian E; Gomes C; Birk B; Williford T; Hernandez TR; Haase C; Zbranek R; van Ravenzwaay B; Landsiedel R
    Arch Toxicol; 2019 Feb; 93(2):401-416. PubMed ID: 30552464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-species conservation of endocrine pathways: a critical analysis of tier 1 fish and rat screening assays with 12 model chemicals.
    Ankley GT; Gray LE
    Environ Toxicol Chem; 2013 Apr; 32(5):1084-7. PubMed ID: 23401061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A testing strategy for the identification of mammalian, systemic endocrine disruptors with particular focus on steroids.
    Kolle SN; Ramirez T; Kamp HG; Buesen R; Flick B; Strauss V; van Ravenzwaay B
    Regul Toxicol Pharmacol; 2012 Jul; 63(2):259-78. PubMed ID: 22554500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fish Physiologically Based Toxicokinetic Modeling Approach for In Vitro-In Vivo and Cross-Species Extrapolation of Endocrine-Disrupting Chemicals in Risk Assessment.
    Xie R; Xu Y; Ma M; Wang Z
    Environ Sci Technol; 2024 Feb; 58(8):3677-3689. PubMed ID: 38354091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of estrogenic binary mixtures in the yeast estrogen screen (YES).
    Ramirez T; Buechse A; Dammann M; Melching-Kollmuß S; Woitkowiak C; van Ravenzwaay B
    Regul Toxicol Pharmacol; 2014 Oct; 70(1):286-96. PubMed ID: 25017362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro to in vivo extrapolation for predicting human equivalent dose of phenolic endocrine disrupting chemicals: PBTK model development, biological pathways, outcomes and performance.
    Xie R; Wang X; Xu Y; Zhang L; Ma M; Wang Z
    Sci Total Environ; 2023 Nov; 897():165271. PubMed ID: 37422235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay.
    Beames T; Moreau M; Roberts LA; Mansouri K; Haider S; Smeltz M; Nicolas CI; Doheny D; Phillips MB; Yoon M; Becker RA; McMullen PD; Andersen ME; Clewell RA; Hartman JK
    Toxicol Appl Pharmacol; 2020 Jan; 387():114774. PubMed ID: 31783037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case study on quantitative in vitro to in vivo extrapolation for environmental esters: Methyl-, propyl- and butylparaben.
    Campbell JL; Yoon M; Clewell HJ
    Toxicology; 2015 Jun; 332():67-76. PubMed ID: 25839974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and evaluation of a harmonized whole body physiologically based pharmacokinetic (PBPK) model for flutamide in rats and its extrapolation to humans.
    Sharma RP; Kumar V; Schuhmacher M; Kolodkin A; Westerhoff HV
    Environ Res; 2020 Mar; 182():108948. PubMed ID: 31841869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of OASIS QSAR Models Using ToxCast™ in Vitro Estrogen and Androgen Receptor Binding Data and Application in an Integrated Endocrine Screening Approach.
    Bhhatarai B; Wilson DM; Price PS; Marty S; Parks AK; Carney E
    Environ Health Perspect; 2016 Sep; 124(9):1453-61. PubMed ID: 27152837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
    LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the analgesic dipyrone as a possible (anti)androgenic endocrine disruptor.
    Passoni MT; Kristensen MN; Morais RN; Woitkowiak C; Boareto AC; da Silva Amaral BA; Grechi N; Dalsenter PR; Munkboel CH; Styrishave B; Kristensen DM; Gomes C; van Ravenzwaay B; Martino-Andrade AJ
    Toxicol Lett; 2018 Mar; 285():139-147. PubMed ID: 29289696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selected bisphenols and phthalates screened for estrogen and androgen disruption by in silico and in vitro methods.
    Dvorakova M; Kejlová K; Rucki M; Jírová D
    Neuro Endocrinol Lett; 2018 Dec; 39(5):409-416. PubMed ID: 30664347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine-disrupting potential of bisphenol A, bisphenol A dimethacrylate, 4-n-nonylphenol, and 4-n-octylphenol in vitro: new data and a brief review.
    Bonefeld-Jørgensen EC; Long M; Hofmeister MV; Vinggaard AM
    Environ Health Perspect; 2007 Dec; 115 Suppl 1(Suppl 1):69-76. PubMed ID: 18174953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the in vivo developmental toxicity of fenarimol from in vitro toxicity data using PBTK modelling-facilitated reverse dosimetry approach.
    Bhateria M; Taneja I; Karsauliya K; Sonker AK; Shibata Y; Sato H; Singh SP; Hisaka A
    Toxicol Appl Pharmacol; 2024 Mar; 484():116879. PubMed ID: 38431230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of metabolic enzymes to improve predictivity of reporter gene assay results for estrogenic and anti-androgenic activity.
    van Vugt-Lussenburg BMA; van der Lee RB; Man HY; Middelhof I; Brouwer A; Besselink H; van der Burg B
    Reprod Toxicol; 2018 Jan; 75():40-48. PubMed ID: 29162470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative methods in vitro for screening of endocrine disruptors.
    Dvořáková M; Kejlová K; Bendová H; Rucki M; Kohout P; Vavrouš A; Jírová D
    Neuro Endocrinol Lett; 2016 Dec; 37(Suppl1):123-131. PubMed ID: 28263540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternatives to in vivo tests to detect endocrine disrupting chemicals (EDCs) in fish and amphibians--screening for estrogen, androgen and thyroid hormone disruption.
    Scholz S; Renner P; Belanger SE; Busquet F; Davi R; Demeneix BA; Denny JS; Léonard M; McMaster ME; Villeneuve DL; Embry MR
    Crit Rev Toxicol; 2013 Jan; 43(1):45-72. PubMed ID: 23190036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-evaluation of the first synthetic estrogen, 1-keto-1,2,3, 4-tetrahydrophenanthrene, and bisphenol A, using both the ovariectomised rat model used in 1933 and additional assays.
    Ashby J; Odum J; Paton D; Lefevre PA; Beresford N; Sumpter JP
    Toxicol Lett; 2000 Jun; 115(3):231-8. PubMed ID: 10814893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of ToxCast Test Results with In Vivo and Other In Vitro Endpoints for Neuro, Endocrine, and Developmental Toxicities: A Case Study Using Endosulfan and Methidathion.
    Silva M; Pham N; Lewis C; Iyer S; Kwok E; Solomon G; Zeise L
    Birth Defects Res B Dev Reprod Toxicol; 2015 Apr; 104(2):71-89. PubMed ID: 26017137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.